文献速递消化系统肿瘤

炎症生物标志物与III期结肠癌患者生存的关联

Association of Inflammatory Biomarkers With Survival Among Patients With Stage III Colon Cancer.
PubMed 文献 · JAMA Oncol · 2023-01-01

该队列研究纳入1494例III期结肠癌患者,检测术后化疗前血浆IL-6、sTNF-αR2和hsCRP水平。最高五分位炎症患者无病生存风险显著增加,调整后风险比分别为IL-6 1.52、sTNF-αR2 1.77、hsCRP 1.65。炎症标志物与塞来昔布干预间未观察到显著交互作用,作者认为需进一步研究抗炎干预能否改善结肠癌结局。

要点

  • 术后化疗前血浆IL-6最高五分位患者无病生存风险显著增加,调整后HR 1.52(95%CI 1.07-2.14)。
  • sTNF-αR2最高五分位患者无病生存风险显著增加,调整后HR 1.77(95%CI 1.23-2.55)。
  • hsCRP最高五分位患者无病生存风险显著增加,调整后HR 1.65(95%CI 1.17-2.34)。

核心结论

  • 该队列研究发现,诊断后较高的炎症水平与III期结肠癌患者更差的生存结局显著相关。
  • 作者认为这一发现需进一步研究,以评估抗炎干预能否改善结肠癌结局。

研究设计与样本

  • 本研究为队列研究,源自美国国家癌症研究所资助的辅助化疗试验CALGB/SWOG 80702。
  • 研究于2010年6月22日至2015年11月20日开展,随访截至2020年8月10日。
  • 共纳入1494例有血浆样本可用于炎症生物标志物检测的患者。
  • 数据分析时间为2021年7月29日至2022年2月27日。

主要发现

  • 中位随访5.9年(IQR 4.7-6.1年),中位年龄61.3岁(IQR 54.0-68.8岁),男性828例(55.4%)。
  • 观察到的复发327例、死亡244例、无病生存事件387例。
  • 血浆样本采集于术后中位6.9周(IQR 5.6-8.1周)。
  • 中位血浆浓度:IL-6为3.8 pg/mL(IQR 2.3-6.2 pg/mL),sTNF-αR2为2.9×10³ pg/mL(IQR 2.3-3.6×10³ pg/mL),hsCRP为2.6 mg/L(IQR 1.2-5.6 mg/L)。
  • 与最低五分位相比,最高五分位炎症患者复发或死亡风险显著增加:IL-6调整后HR 1.52(95%CI 1.07-2.14;趋势P=0.01),sTNF-αR2调整后HR 1.77(95%CI 1.23-2.55;趋势P<0.001),hsCRP调整后HR 1.65(95%CI 1.17-2.34;趋势P=0.006)。

关键数值与推荐

  • 炎症生物标志物与塞来昔布干预之间未观察到对无病生存的显著交互作用。
  • 复发无生存和总生存观察到相似结果。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者认为这一发现需进一步研究,以评估抗炎干预能否改善结肠癌结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The association of chronic inflammation with colorectal cancer recurrence and death is not well understood, and data from large well-designed prospective cohorts are limited. OBJECTIVE: To assess the associations of inflammatory biomarkers with survival among patients with stage III colon cancer. DESIGN, SETTING, AND PARTICIPANTS: This cohort study was derived from a National Cancer Institute-sponsored adjuvant chemotherapy trial Cancer and Leukemia Group B/Southwest Oncology Group 80702 (CALGB/SWOG 80702) conducted between June 22, 2010, and November 20, 2015, with follow-up ending on August 10, 2020. A total of 1494 patients with plasma samples available for inflammatory biomarker assays were included. Data were analyzed from July 29, 2021, to February 27, 2022. EXPOSURES: Plasma inflammatory biomarkers (interleukin 6 [IL-6], soluble tumor necrosis factor α receptor 2 [sTNF-αR2], and high-sensitivity C-reactive protein [hsCRP]; quintiles) that were assayed 3 to 8 weeks after surgery but before chemotherapy randomization. MAIN OUTCOMES AND MEASURES: The primary outcome was disease-free survival, defined as time from randomization to colon cancer recurrence or death from any cause. Secondary outcomes were recurrence-free survival and overall survival. Hazard ratios for the associations of inflammatory biomarkers and survival were estimated via Cox proportional hazards regression. RESULTS: Of 1494 patients (median follow-up, 5.9 years [IQR, 4.7-6.1 years]), the median age was 61.3 years (IQR, 54.0-68.8 years), 828 (55.4%) were male, and 327 recurrences, 244 deaths, and 387 events for disease-free survival were observed. Plasma samples were collected at a median of 6.9 weeks (IQR, 5.6-8.1 weeks) after surgery. The median plasma concentration was 3.8 pg/mL (IQR, 2.3-6.2 pg/mL) for IL-6, 2.9 × 103 pg/mL (IQR, 2.3-3.6 × 103 pg/mL) for sTNF-αR2, and 2.6 mg/L (IQR, 1.2-5.6 mg/L) for hsCRP. Compared with patients in the lowest quintile of inflammation, patients in the highest quintile of inflammation had a significantly increased risk of recurrence or death (adjusted hazard ratios for IL-6: 1.52 [95% CI, 1.07-2.14]; P = .01 for trend; for sTNF-αR2: 1.77 [95% CI, 1.23-2.55]; P < .001 for trend; and for hsCRP: 1.65 [95% CI, 1.17-2.34]; P = .006 for trend). Additionally, a significant interaction was not observed between inflammatory biomarkers and celecoxib intervention for disease-free survival. Similar results were observed for recurrence-free survival and overall survival. CONCLUSIONS AND RELEVANCE: This cohort study found that higher inflammation after diagnosis was significantly associated with worse survival outcomes among patients with stage III colon cancer. This finding warrants further investigation to evaluate whether anti-inflammatory interventions may improve colon cancer outcomes. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01150045.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Cheng E, Shi Q, Shields AF, et al. Association of Inflammatory Biomarkers With Survival Among Patients With Stage III Colon Cancer. JAMA Oncol. 2023. PMID: 36701146. doi:10.1001/jamaoncol.2022.6911

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。